Endometrial Cancer
Phase II clinical trial of cell-signaling protein inhibitor seeks patients
Published in Women's Health Weekly, July 21st, 2005
This nonrandomized study will evaluate the clinical benefit of AP23573 in well-characterized endometrial cancer patients. Up to approximately 45 patients will be enrolled in the trial at several centers in the United States and Europe. AP23573 will be administered intravenously using a daily dosing regimen. Patients will be followed for at least 6 months after enrollment but may continue on AP23573 if they have clinical benefit.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Chronic Cough
Airway infection coinciding with menopause sets up chronic dry cough - Coronary Heart Disease
Birth weight and adult BMI are prognostic indicators of CHD in women - Health Policy
Women's health suffers under welfare reform, study says - Lung Cancer
Poor lung function increases cancer risk, especially in women - Pelvic Floor Disorders
Survey: Women don't seek medical help until they become incontinent - Adrenergic Receptors
Adrenergic receptors analyzed, oocyte and embryonic expression defined - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
